|
JPS57106673A
(en)
|
1980-12-24 |
1982-07-02 |
Chugai Pharmaceut Co Ltd |
Dibenzo(b,f)(1,4)oxazepin derivative
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US20050164301A1
(en)
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
CN101898945B
(zh)
|
2010-07-27 |
2013-05-08 |
大连理工大学 |
盐析萃取发酵液中丙酮和丁醇的方法
|
|
EP3147297B1
(en)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies directed against icos and uses thereof
|
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
RS60614B1
(sr)
|
2015-03-23 |
2020-08-31 |
Jounce Therapeutics Inc |
Antitela za icos
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN110267990B
(zh)
*
|
2016-08-30 |
2023-11-07 |
Xencor股份有限公司 |
结合共刺激性和检查点受体的双特异性免疫调节抗体
|
|
WO2018115859A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
EP3559041A1
(en)
*
|
2016-12-20 |
2019-10-30 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
WO2018129553A1
(en)
|
2017-01-09 |
2018-07-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-tim-3 antibodies
|
|
US20200024351A1
(en)
*
|
2017-04-03 |
2020-01-23 |
Jounce Therapeutics, Inc. |
Compositions and Methods for the Treatment of Cancer
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
SG11201909395TA
(en)
*
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
JP2020525427A
(ja)
*
|
2017-06-21 |
2020-08-27 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
癌を処置するための方法
|
|
EP3502140A1
(en)
*
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|